Printed From BioPortfolio.com
AACR 2018: Neoadjuvant nivolumab was safe, yielded pathologic responses in patients with resectable lung cancer
11:04 EDT 16 Apr 2018 | ecancermedicalscience
The anti-PD1 immunotherapy nivolumab given prior to surgical resection of stage 1-3 non-small cell lung cancer (NSCLC) was safe and resulted in major pathological responses in 45 percent of the patients, according to data from a clinical trial presented...
Original Article: AACR 2018: Neoadjuvant nivolumab was safe, yielded pathologic responses in patients with resectable lung cancer
